NCT02474927View on ClinicalTrials.gov

Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2015

Primary Completion Date

November 9, 2020

Study Completion Date

July 26, 2021

Conditions

Lung Transplant Rejection

Interventions

DRUG

Carfilzomib

Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)

Trial Locations (1)

15213

University of Pittsburgh Medical Center, Pittsburgh

All Listed Sponsors

lead

John F. McDyer, MD

OTHER

NCT02474927 - Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation | Biotech Hunter | Biotech Hunter